



- (51) **International Patent Classification:**
G01N 33/68 (2006.01)
- (21) **International Application Number:**
PCT/US2022/040890
- (22) **International Filing Date:**
19 August 2022 (19.08.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/235,594 20 August 2021 (20.08.2021) US
- (71) **Applicant: DEWPOINT THERAPEUTICS, INC.**
[US/US]; 451 D Street, Suite 104, Boston, Massachusetts 02210 (US).
- (72) **Inventors: SOOKIASIAN, Danielle Lauren;** c/o Dewpoint Therapeutics, Inc., 451 D Street, Suite 104, Boston, Massachusetts 02210 (US). **NUNES, Roberto Neves;** c/o Dewpoint Therapeutics, Inc., 451 D Street, Suite 104, Boston, Massachusetts 02210 (US). **DANDLIKER, Peter Jeffrey;** c/o Dewpoint Therapeutics, Inc., 451 D Street, Suite 104, Boston, Massachusetts 02210 (US). **LEVIN,**

Benjamin Diamon; c/o Dewpoint Therapeutics, Inc., 451 D Street, Suite 104, Boston, Massachusetts 02210 (US). **WIJAYA, Juwina;** c/o Dewpoint Therapeutics, Inc., 451 D Street, Suite 104, Boston, Massachusetts 02210 (US). **ROUSTAYAN, Kamran Danielle Rizzolo;** c/o Dewpoint Therapeutics, Inc., 451 D Street, Suite 104, Boston, Massachusetts 02210 (US).

(74) **Agent: CHAPMAN, John D et al.;** Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) **Title:** METHODS OF ISOLATING A COMPOSITION COMPRISING A TARGET MOLECULE




FIG. 1

(57) **Abstract:** The present disclosure provides immunoprecipitation (IP) methods such as antibody-mediated techniques using a bridged tandem antibody complex. In other aspects, the present disclosure also provides compositions, kits, and systems useful for use in the immunoprecipitation methods described herein.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*